 BOSTON, March 24, 2021 PRNewswire -- NeuroBo Pharmaceuticals, Inc. Nasdaq: NRBO, a clinical-stage biotechnology company, today announced that it has received approval of an amendment to its Contingent Value Rights CVR agreement from a majority of the holders of a majority of the outstanding CVRs, incentivizing the evaluation of Gemcabene as a treatment for COVID-19. The CVRs were distributed to the holders of Gemphire Therapeutics, Inc. common stock on December 30, 2019, immediately prior to its merger with NeuroBo Pharmaceuticals, Inc. The CVR amendment will allow NeuroBo to pursue Gemcabene as a therapy for COVID-19, with its own resources. 